Kyongbo Pharmaceutical Co Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: -0.004x

Kyongbo Pharmaceutical Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has a cash flow conversion efficiency ratio of -0.004x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-565.17 Million ≈ $-383.01K USD) by net assets (₩146.99 Billion ≈ $99.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Kyongbo Pharmaceutical Co Ltd (2014–2025)

Cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. This chart illustrates how Kyongbo Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 214390 share price today for real-time trading data and today's change.

Kyongbo Pharmaceutical Co Ltd Cash Flow Conversion Ratio Explained

Kyongbo Pharmaceutical Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Kyongbo Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Also see Kyongbo Pharmaceutical Co Ltd stock valuation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
SV Investment Corporation KQ:289080	0.019x
Capstone Energy Plus, Inc. Common Stock NASDAQ:CEPL	0.182x
BIEN SPAREB.AS NK 34375 F:JX0	-0.180x
Silvercrest Asset Management Group Inc NASDAQ:SAMG	0.175x
China Silver Group Limited F:2CS	0.015x
Hanshin Const KO:004960	-0.029x
Telechips Inc KQ:054450	0.019x
Auburn National Bancorporation Inc NASDAQ:AUBN	0.038x

Annual Cash Flow Conversion Efficiency for Kyongbo Pharmaceutical Co Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2025. Review 214390 free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩145.74 Billion ≈ $98.76 Million	₩7.46 Billion ≈ $5.05 Million	0.051x	+4914.11%
2024-12-31	₩146.15 Billion ≈ $99.05 Million	₩149.12 Million ≈ $101.05K	0.001x	-96.96%
2023-12-31	₩144.38 Billion ≈ $97.85 Million	₩4.84 Billion ≈ $3.28 Million	0.034x	-52.39%
2022-12-31	₩143.70 Billion ≈ $97.39 Million	₩10.13 Billion ≈ $6.86 Million	0.070x	-42.86%
2021-12-31	₩145.70 Billion ≈ $98.74 Million	₩17.97 Billion ≈ $12.18 Million	0.123x	-7.45%
2020-12-31	₩156.06 Billion ≈ $105.76 Million	₩20.80 Billion ≈ $14.09 Million	0.133x	-16.02%
2019-12-31	₩149.16 Billion ≈ $101.09 Million	₩23.67 Billion ≈ $16.04 Million	0.159x	+2177.40%
2018-12-31	₩149.01 Billion ≈ $100.98 Million	₩-1.14 Billion ≈ $-771.31K	-0.008x	-104.19%
2017-12-31	₩141.51 Billion ≈ $95.90 Million	₩25.81 Billion ≈ $17.49 Million	0.182x	-6.84%
2016-12-31	₩129.40 Billion ≈ $87.69 Million	₩25.33 Billion ≈ $17.16 Million	0.196x	+466.96%
2015-12-31	₩122.82 Billion ≈ $83.23 Million	₩4.24 Billion ≈ $2.87 Million	0.035x	-85.29%
2014-12-31	₩68.33 Billion ≈ $46.31 Million	₩16.04 Billion ≈ $10.87 Million	0.235x	--

About Kyongbo Pharmaceutical Co Ltd

KO:214390 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$83.11 Million

₩122.64 Billion KRW

Market Cap Rank

#19725 Global

#1014 in Korea

Share Price

₩5130.00

Change (1 day)

-0.19%

52-Week Range

₩4945.00 - ₩8550.00

All Time High

₩19100.23